2131803-90-0

2131803-90-0 structure

Name: WYC-209
Chemical Name: WYC-209
CAS Number: 2131803-90-0
Molecular Formula: C₂₀H₂₀N₂O₃S
Molecular Weight: 368.45
Catalog: Signaling Pathways Metabolic Enzyme/Protease RAR/RXR
Create Date: 2019-06-29 18:01:20
Modify Date: 2024-01-04 20:55:23
WYC-209, a synthetic retinoid, inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs) with an IC50 of 0.19 μM, has long-term effects and little toxicity, and induces TRCs apoptosis primarily via the caspase 3 pathway. The primary cellular target of WYC-209 is retinoic acid receptor (RAR)[1].

Name	WYC-209

Description	WYC-209, a synthetic retinoid, inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs) with an IC50 of 0.19 μM, has long-term effects and little toxicity, and induces TRCs apoptosis primarily via the caspase 3 pathway. The primary cellular target of WYC-209 is retinoic acid receptor (RAR)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR
Target	Retinoic acid receptor[1]
In Vitro	WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect[1]. Apoptosis Analysis[1] Cell Line: A2780, A549, MCF-7, MDA-MB-435s, A375 cells Concentration: 10 μM Incubation Time: 24 hours Result: TRCs failed to resume growth 5 days after the drug washout.
In Vivo	WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases[1]. Animal Model: Female immune-competent C57BL/6 mice[1] Dosage: 0.022, 0.22 mg/kg Administration: Intravenous injection; once every two days for 25 days Result: Four out of eight mice formed lung metastases at dose of 0.022 mg /kg, only one out of eight mice formed lung metastases at dose of 0.22 mg/kg.
References	[1]. Chen J, et al. Inhibition of cancer stem cell like cells by a synthetic retinoid. Nat Commun. 2018 Apr 11;9(1):1406.